舒泰神(300204.SZ)：STSP-0902滴眼液(用于治疗神经营养性角膜炎)获得I期临床研究总结报告

Core Viewpoint - The company Shuyou Shen (300204.SZ) has recently obtained the Phase I clinical study summary report for STSP-0902 eye drops, indicating positive safety and tolerability results in healthy subjects [1] Group 1: Clinical Study Results - STSP-0902 eye drops demonstrated good overall safety and tolerability with most adverse events classified as CTCAE Grade 1 [1] - All drug-related adverse events were mild and self-limiting localized ocular reactions [1] - Pharmacokinetic results showed that the trial drug was detectable in all tear samples up to 6 hours after a single dose [1] Group 2: Future Research Implications - No systemic drug exposure or immunogenicity was observed after both single and multiple doses [1] - The study results support the initiation of further clinical trials in patients with neurotrophic keratitis [1]